

ID	Research Ethics Committee Reference Number (REC)	Integrated Research Application System Number (IRAS)	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed?	Maximum Number Of Patients Agreed?	Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial	Comments
22756	16/YH/0052	185325	Evaluation of the effectiveness of the abatacept (ORENCIA®) intravenous and formulation Patient Alert Cards in patients with rheumatoid arthritis in a sample of European Economic Area countries	Number Agreed	10	10	Date Agreed	26/04/2017	1	26/04/2017	1	Recruitment Finished	

ID	Research Ethics Committee Reference Number (REC)	Integrated Research Application System Number (IRAS)	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed?	Maximum Number Of Patients Agreed?	Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial	Comments
24059	16/YH/0052	185325	Evaluation of the effectiveness of the abatacept (ORENCIA®) intravenous and formulation Patient Alert Cards in patients with rheumatoid arthritis in a sample of European Economic Area countries	Number Agreed	10	10	Date Agreed	26/04/2017	1	26/04/2017	1	Recruitment Finished	

ID	Research Ethics Committee Reference Number (REC)	Integrated Research Application System Number (IRAS)	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed?	Maximum Number Of Patients Agreed?	Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial	Comments
25574	16/YH/0052	185325	Evaluation of the effectiveness of the abatacept (ORENCIA®) intravenous and formulation Patient Alert Cards in patients with rheumatoid arthritis in a sample of European Economic Area countries	Number Agreed	10	10	Date Agreed	26/04/2017	1	26/04/2017	0	Recruitment Finished	
25579	17/EM/0075	222172	High Energy High Protein Tube Feed Study	Number Agreed	5	5	Date Agreed	23/05/2017	5	13/12/2017	0	Withdrawn By Host	Patients approached lacked capacity to consent.

ID	Research Ethics Committee Reference Number (REC)	Integrated Research Application System Number (IRAS)	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed?	Maximum Number Of Patients Agreed?	Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial	Comments
27346	16/YH/0052	185325	Evaluation of the effectiveness of the abatacept (ORENCIA®) intravenous and formulation Patient Alert Cards in patients with rheumatoid arthritis in a sample of European Economic Area countries	Number Agreed	10	10	Date Agreed	26/04/2017	1	26/04/2017	0	Recruitment Finished	
27347	17/EM/0075	222172	High Energy High Protein Tube Feed Study	Number Agreed	5	5	Date Agreed	23/05/2017	5	13/12/2017	0	Withdrawn By Host	Patients approached lacked capacity to consent.
27348	14/LO/0203	137863	CLARITY	Number Agreed	12	12	Date Agreed	31/12/2016	7			Recruitment Finished	